Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

    Bayer announced the start of a Phase III clinical development program OCEANIC to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor, as a potential new treatment in patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

  • NPPA will celebrate its Silver Jubilee

    To commemorate 25 years of existence of National Pharmaceutical Pricing Authority (NPPA), a programme will be organised at the Dr. Ambedkar International Centre, Janpath. Union Minister for Chemicals & Fertilizers and Health & Family Welfare Dr. Mansukh Mandaviya will grace the occasion as Chief Guest. MoS for Chemicals & Fertilizers and New & Renewable Energy will grace the occasion as Guest of Honour.

  • Novartis Scemblix gets EU approval

    Novartis said its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to other therapies, as reported by Reuters.

    Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments.

  • Nigeria introduces Bharat Biotech Rotavac vaccine for children

    Bharat Biotech International Limited rotavirus oral vaccine Rotavac has been introduced by Nigeria to immunize its children from the life- threatening diarrhoeal disease that affects millions of children worldwide.

    Nigeria currently accounts for 14 percent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world. Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria.

  • Government revised guidelines of PLI scheme for medical devices

    Recently Government has revised guidelines for the production linked incentive (PLI) scheme for promoting domestic manufacturing of medical devices.

  • Moderna sues Pfizer BioNTech over patent infringement

    Moderna is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Dusseldorf in Germany. Moderna believes that Pfizer and BioNTech copied two key features of it patented technologies.

  • First African medicine to prevent malaria approved by WHO

    Local supply of a medicine used to prevent malaria across Africa received a boost recently, as the World Health Organization (WHO) issued a quality certification to the first African manufacturer of a key antimalarial drug used to prevent infection in pregnant women and children. Called pre- qualification, this certification will enable Kenyan manufacturer Universal Corporation Ltd (UCL) to support regional efforts to combat malaria through local production of high-quality sulfadoxine-pyrimethamine (SP).

  • Pfizer and BioNTech releases supported data for children vaccination

    Pfizer Inc. and BioNTech SE announced updated efficacy results from a Phase 2/3 trial evaluating a three 3 ug dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data collected in March and April 2022.

  • Microscopy reveals mechanism behind new CRISPR tool

    New research from Cornell offers insights into a line of CRISPR systems, which could lead to promising antiviral and tissue engineering tools in animal and plants.

    The research by Ailong Ke, the Robert J. Appel Professor of molecular biology and genetics in the College of Arts and Sciences, and Stan J.J. Brouns at Delft University of Technology in the Netherlands, focuses on a newly discovered CRISPR RNA-guided Caspase system, otherwise known as Craspase.

  • Universal Flu Vaccine Protects Against Variants of Both Influenza A and B Viruses : Researcher

    A new universal flu vaccine protects against diverse variants of both influenza A and B viruses in mice, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

    The researchers designed a single, universal influenza vaccine candidate with key cross-protective, less variable parts of the influenza A and B viruses: multi-neuraminidase protein subtypes known to be major antiviral drug targets and the universally conserved M2 ectodomain protein.

Subscribe to Pharma News